Neuland Laboratories · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Despite capacity readiness, full utilization depends on customer-side factors including drug product manufacturing qualification, regulatory filings across markets, and supply chain coordination—creating execution risk beyond Neuland's direct control.
Analyst Chaksha from Whitepine raised concern that commercial molecule count remains at 9 with significant dropouts over four years, questioning whether the 20% growth target is achievable without either more molecules or larger-value partnerships.
Working capital days extended to 145 from 94 historically, with inventory increasing 170 crore in 9M versus PAT increase of 150 crore. Analyst Archel from Ananta questioned whether profits are inventory-driven. Management attributed this to ramp-up preparation but acknowledged quarterly volatility.
Operational issues at a customer end caused delayed shipments for Paliperidone, a high-margin specialty product. Management indicated resolution likely only in FY27, removing a key margin contributor from the current year outlook.
